

**WEST**

Help

Logout

Interrupt

Main Menu

Search Form

Posting Counts

Show S Numbers

Edit S Numbers

Preferences

**Search Results -**

Terms	Documents
EUGENOL AND CANCER AND PHARMACEUTICAL	41

Database:

☐ US Patents Full-Text Database  
☐ JPO Abstracts Database  
☐ EPO Abstracts Database  
☐ Derwent World Patents Index  
☐ IBM Technical Disclosure Bulletins

L4 AND EUGENOL.CLM. AND EUGENOL.TI.

Refine Search:

Clear

**Search History**

Today's Date: 1/17/2001

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT,JPAB,EPAB,DWPI,TDBD	EUGENOL AND CANCER AND PHARMACEUTICAL	41	<u>L4</u>
USPT,JPAB,EPAB,DWPI,TDBD	EUGENOL NEAR10 PHARMACEUTICAL	5	<u>L3</u>
USPT,JPAB,EPAB,DWPI,TDBD	EUGENOL NEAR10 CANCER AND PHARMACEUTICAL	0	<u>L2</u>
USPT,JPAB,EPAB,DWPI,TDBD	EUGENOL NEAR10 CANCER NEAR20 PHARMACEUTICAL	0	<u>L1</u>

L12 ANSWER 11 OF 33 CAPLUS COPYRIGHT 2001 ACS

AN 1998:101607 CAPLUS

DN 128:213361

TI Antianaphylactic properties of eugenol

AU Kim, Hyung-Min; Lee, Eun-Hee; Kim, Chang-Young; Chung, Jong-Gab; Kim, Sang-Hyun; Lim, Jong-Pil; Shin, Tae-Yong

CS Department of Oriental Pharmacy, College of Pharmacy, Wonkwang University,

Chonbuk, 570-749, S. Korea

SO Pharmacol. Res. (1997), 36(6), 475-480

CODEN: PHMREP; ISSN: 1043-6618

PB Academic Press Ltd.

DT Journal

LA English

CC 1-12 (Pharmacology)

AB The effects of eugenol, a major component of clove, on anaphylaxis were evaluated in rats. Eugenol inhibited compd. 48/80-induced systemic anaphylaxis 100% with a dose of 10  $\mu$ g g<sup>-1</sup> body wt. (BW). While serum levels of histamine were markedly elevated after compd. 48/80 injection

in all groups of rats, rats injected with eugenol showed a significant redn. in serum histamine levels. Eugenol also inhibited passive cutaneous anaphylaxis activated by anti-dinitrophenyl (DNP) IgE. Eugenol dose-dependently inhibited histamine release from the rat peritoneal mast cells (RPMC) activated by compd. 48/80 or anti-DNP IgE. The morphol. examn. clearly showed that eugenol prevented the anaphylactic degranulation of RPMC. Moreover, eugenol (10  $\mu$ g ml<sup>-1</sup>) had a significant inhibitory effect on anti-DNP IgE-induced tumor necrosis factor- $\alpha$  prodn. These results suggest that eugenol has antianaphylactic properties by preventing mast cell degranulation.

ST antianaphylactic eugenol

IT Natural products (**pharmaceutical**)

RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)

(anti-anaphylactic activity of **eugenol**)

IT Mast cell degranulation

(eugenol anti-anaphylactic activity in relation to inhibition of)

IT Tumor necrosis factor  $\alpha$ .

RL: MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative)

(eugenol anti-anaphylactic activity in relation to inhibition of mast cell formation of)

IT Anaphylaxis

(eugenol as inhibitor of)

IT Hypersensitivity

(type I; anti-anaphylactic activity of eugenol in relation to)

IT 97-53-0, Eugenol

PL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)

(anti-anaphylactic activity of)

L12 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2001 ACS

AN 1997:618647 CAPLUS

DN 127:298560

TI Odorless and nonirritant cosmetics containing eugenol and its derivatives

IN Yoshimura, Masanori; Watanabe, Yoji; Yoshiki, Mayumi; Takenaka, Gen; Yoshimune, Sadanori

PA Lion Corp., Japan

SO Jpn. Kokai Tokkyo Koho, 5 pp.

1282

CODEN: JKXXAF  
DT Patent  
LA Japanese  
IC ICM A61K007-00  
ICS A61K007-00; A61K007-48; A61K031-09; A61K031-22; A61K031-60  
CC 62-4 (Essential Oils and Cosmetics)  
Section cross-reference(s): 63  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 09241116	A2	19970916	JP 1996-75164	19960305

AB Title cosmetics, useful for improvement of blood circulation and treatment of dropsy and myalgia, contain eugenol derivs. selected acetyeugenol (I), methyleugenol, methylisoeugenol, ethyleugenol, ethylisoeugenol, and eugenol salicylate and 0.05-0.7 wt.% (based on the derivs.) eugenol (II). An odorless compn. contg. I 1.0, II 0.001, and EtOH 50.0 wt. parts was effective in treatment of dropsy. Formulation examples of aerosols and gels are given.

ST odorless cosmetic eugenol deriv dropsy treatment; myalgia treatment nonirritant cosmetic eugenol deriv; blood circulation improvement odorless cosmetic eugenol

IT Diseases (animal)  
(dropsy, treatment of; odorless and nonirritant cosmetics contg. eugenol and its derivs. for blood circulation improvement)

IT Muscle diseases  
(myalgia, treatment of; odorless and nonirritant cosmetics contg. eugenol and its derivs. for blood circulation improvement)

IT Blood flow  
Cosmetics  
Skin preparations (**pharmaceutical**)  
(odorless and nonirritant cosmetics contg. **eugenol** and its derivs. for blood circulation improvement)

IT 93-15-2, Methyleugenol 93-16-3, Methylisoeugenol 93-28-7, Acetyeugenol 97-53-0, Eugenol 1755-54-0, Ethyleugenol 7784-67-0, Ethylisoeugenol 160431-51-6, Eugenol salicylate  
FL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(odorless and nonirritant cosmetics contg. eugenol and its derivs. for blood circulation improvement)

L12 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2001 ACS

AN 1995:324830 CAPLUS

DN 122:89446

TI Pharmaceutical solutions containing essential oils for preparation of local anesthetics

IN Jamouille, Jean Claude; Balard, Philippe

PA Algovital SarL, Fr.

SO Fr. Demande, 7 pp.

CODEN: FRXXBL

DT Patent

LA French

IC ICM A61K035-78

CC 63-6 (Pharmaceuticals)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2704429	A1	19941104	FR 1993-5407	19930430
	FR 2704429	B3	19950713		

AB An alk. soln. which contains essential oils is disclosed. The soln. is mixed with local anesthetics (e.g. lidocaine) for topical administration. A soln. contained Sepigel 2.5, Oramix 305 2.5, clove oil 10, menthol 10,

Ylang-Ylang oil 10, and NaOH N/10 q.s. 100%.

ST pharmaceutical soln essential oil local anesthetic; menthol clove oil  
local anesthetic soln

IT Essential oils  
FL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(clove, pharmaceutical soln. contg. essential oils for prepn. of local  
anesthetics)

IT Essential oils  
FL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(clove stem, pharmaceutical soln. contg. essential oils for prepn. of  
local anesthetics)

IT Castor oil  
FL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(ethoxylated, pharmaceutical soln. contg. essential oils for prepn. of  
local anesthetics)

IT Anesthetics  
(local, pharmaceutical soln. contg. essential oils for prepn. of local  
anesthetics)

IT Essential oils  
FL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(mint, Mentha, pharmaceutical soln. contg. essential oils for prepn.  
of  
local anesthetics)

IT Fats and Glyceridic oils  
FL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(wheat germ, pharmaceutical soln. contg. essential oils for prepn. of  
local anesthetics)

IT Essential oils  
FL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(ylang-ylang, pharmaceutical soln. contg. essential oils for prepn. of  
local anesthetics)

IT 97-53-0, **Eugenol** 100-51-6, Benzyl alcohol, biological studies  
1490-04-6, Menthol  
FL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(**pharmaceutical** soln. contg. essential oils for prepn. of  
local anesthetics)

L12 ANSWER 14 OF 33 CAPLUS COPYRIGHT 2001 ACS  
AN 1991:115063 CAPLUS  
EN 114:115063  
TI Eugenol-isoeugenol mixtures for treatment of AIDS  
PA Kaempgen, Dieter, Fed. Rep. Ger.  
SO Ger. Offen., 2 pp.  
CODEN: GWXXBX  
DT Patent  
LA German  
IC ICM C07C043-23  
ICS A61K031-085  
CC 1-5 (Pharmacology)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3829200	A1	19900301	DE 1988-3829200	19880829
AB	A compn. for treatment of AIDS contains engenol and isoengenol. Natural plant products contg. the compds., e.g. clove oil, may also be used. Treatment of AIDS patients with 2.5 mg clove oil/day resulted in complete elimination of disease symptoms and survival for .gtoreq.1 yr.				
ST	eugenol isoengenol AIDS treatment; clove oil AIDS treatment				
IT	Clove (exts. of, for AIDS treatment)				
IT	Immunodeficiency (acquired immune deficiency syndrome, treatment of, eugenol-isoeugenol mixt. in)				
IT	Oils, essential FL: BIOL (Biological study) (clove, AIDS treatment with)				

IT **Pharmaceutical** dosage forms  
 (dragees, **eugenol**-isoeugenol mixt. in, for AIDS treatment)  
 IT **Pharmaceutical** dosage forms  
 (liqs., **eugenol**-isoeugenol mixt. in, for AIDS treatment)  
 IT **Pharmaceutical** dosage forms  
 (powders, **eugenol**-isoeugenol mixt. in, for AIDS treatment)  
 IT **Pharmaceutical** dosage forms  
 (tablets, **eugenol**-isoeugenol mixt. in, for AIDS treatment)  
 IT 91602-09-4  
 FL: BIOL (Biological study)  
 (AIDS treatment with)

L12 ANSWER 16 OF 33 CAPLUS COPYRIGHT 2001 ACS  
 AN 1990:132456 CAPLUS  
 DN 112:132456  
 TI Eugenol enhancement of transdermal drug delivery  
 IN Leonard, Thomas W.; Mikula, Karol K.; Schlesinger, Marcia S.  
 PA American Home Products Corp., USA  
 SO U.S., 4 pp.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 IC ICM A61K031-045  
 NCL 514724000  
 CC 1-2 (Pharmacology)  
 Section cross-reference(s): 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4888362	A	19891219	US 1987-3983	19870116
AB	Disclosed herein are compns. and methods for enhancing the transdermal delivery of physiol. active agents across mammalian skin or membranes and which comprise a precutaneous transfer enhancing amt. of eugenol and a drug. An enhanced percutaneous diffusion of albuterol through nude mouse skin from a formulation contg. 62% by wt. eugenol was demonstrated.				
ST	eugenol transdermal drug				
IT	Drug bioavailability (from transdermal formulation, eugenol enhancement of)				
IT	<b>Pharmaceutical</b> dosage forms (transdermal, <b>eugenol</b> as absorption potentiator for)				
IT	97-53-0, <b>Eugenol</b> PL: BIOL (Biological study) ( <b>pharmaceutical</b> transdermal absorption enhancement by)				
IT	50-23-7, Hydrocortisone 18559-94-9, Albuterol PL: BIOL (Biological study) (transdermal absorption of, eugenol enhancement of)				

L12 ANSWER 18 OF 33 CAPLUS COPYRIGHT 2001 ACS  
 AN 1985:427328 CAPLUS  
 DN 103:27328  
 TI Ophthalmic pharmaceuticals  
 IN Oita, Nicolaie; Sunel, Valeriu; Vilcu, Ilarion; Lazar, Mihai; Calin, Ada; Baidan, Nastase  
 PA Intreprinderea de Medicamente "Biofarm", Rom.  
 SO Rom., 2 pp.  
 CODEN: RUXXA3  
 DT Patent  
 LA Romanian  
 IC A61K009-08; A61K009-06  
 CC 63-6 (Pharmaceuticals)  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	RO 84026	B	19840512	RO 1982-107359	19820426
AB	An ophthalmic <b>pharmaceutical</b> comprises <b>eugenol</b> [97-53-0] 0.5-1.0, or methyleugenol [93-15-2], or clove oil, acetyl				

*Ref V*

rutoside [2328-13-4] 1-5, cysteine [52-90-4] 0.5-1.0, and MgCl2 0.5-1.0  
 g in ointment or soln.  
 ST ophthalmic **pharmaceutical** acetylruoside **eugenol**;  
 clove oil ophthalmic pharmaceutical  
 IT Oils  
 FL: BIOL (Biological study)  
 (clove, ophthalmic **pharmaceutical** contg. **eugenol**  
 oil and)  
 IT 52-90-4, biological studies 93-15-2 97-53-0 2328-13-4  
 FL: BIOL (Biological study)  
 (ophthalmic pharmaceutical contg.)  
 IT 7786-30-3, biological studies  
 FL: BIOL (Biological study)  
 (ophthalmic **pharmaceutical** contg. **eugenol** and)

L12 ANSWER 23 OF 33 INPADOC COPYRIGHT 2001 EPO

LEVEL 1

AN 39857095 INPADOC  
 TI BACTERICIDAL **PHARMACEUTICAL** COMPOSITION CONTAINING  
 CHLORHEXIDINE AND **EUGENOL**  
 IN LUC, JOELLE; TOSELLI, DOMINIQUE  
 INS LUC JOELLE; TOSELLI DOMINIQUE  
 INA FR; FR  
 PA PIERRE FABRE MEDICAMENT  
 PAS PF MEDICAMENT  
 PAA FR  
 LA French  
 DT Patent  
 FIT WOAI PUBL.OF THE INT.APPL. WITH INT.SEARCH REPORT  
 FI WO 9309770 A1 19930527  
 DS RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE  
 W: CA JP US  
 AI WO 1992-FR1047 A 19921112  
 EPAI FR 1991-13919 A 19911113  
 OSCA 119:188673  
 OSDW 93-182218  
 ICM (5) A61K031-155  
 ICI (5) A61K031-155, (5) A61K031:085

L12 ANSWER 32 OF 33 PATOSWO COPYRIGHT 2001 WPLA  
 AN 1993:168134 PATOSWO ED 19930620 EW 199321 FS OS  
 TI BACTERICIDAL **PHARMACEUTICAL** COMPOSITION CONTAINING  
 CHLORHEXIDINE AND **EUGENOL**.  
 IN LUC, JOELLE, FR;  
 TOSELLI, DOMINIQUE, FR  
 PA PIERRE FABRE MEDICAMENT, FR  
 OS WLD1993024 WO 9309770 A1 0026  
 SO PCT-GAZETTE-930527  
 DT Patent  
 LA Application in French  
 DS W CA; W JP; W US;  
 RW AT; RW BE; RW CH; RW DE; RW DK; RW ES; RW FR; RW GB; RW GR; RW IE;  
 RW  
 IT; RW LU; RW MC; RW NL; RW SE  
 FIT WOAI PCT-PUBLICATION  
 FI WO 9309770 A1 19930527  
 OD 19930527  
 AI WO 1992-FR1047 19921112  
 PRAI FR 1991-13919 19911113  
 IC ICM A61K031-155  
 ICI A61K031-155 A61K031:085.  
 ABEN The present invention relates to a bactericidal pharmaceutical  
 composition characterized in that it is comprised of a synergic  
 association of chlorhexidine and eugenol.  
 FA ICI; INA; PAA; ABEN; PRAI

Ref X

=> log off

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF  
LOGOFF? (Y)/N/HOLD:y

STN INTERNATIONAL LOGOFF AT 09:59:11 ON 17 JAN 2001

log hold

L8 ANSWER 2 OF 3 TOXLIT  
AN 1991:3807 TOXLIT  
DN CA-113-237854W  
TI Topical pharmaceutical liquids containing indomethacin and solubility  
enhancers.  
AU Inagi T; Inoue M; Muramatsu T  
SO (1990). Jpn. Kokai Tokkyo Koho PATENT NO. 90196718 08/03/90 (Kohjin Co.,  
Ltd.).  
CY Japan  
ET Patent  
FS CA  
LA Japanese  
OS CA 113:237854  
EM 199101  
AB . . . topical pharmaceutical liq. contains 0.1-5% indomethacin 0.1-5  
and 0.3-10% a soly. enhancer selected from limonene, pinene, camphene,  
citronellol, terpineol, camphor, **eugenol**, etc. Thus, a liq.  
**pharmaceutical** contained indomethacin 1.0, limonene 2.0, EtOH  
50.0, diisopropanolamine 0.5%, and distd. **water** balance.